Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
about
Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial InfectionsRecent trends: Medical management of infectious keratitisOcular penetration of topically applied 1% tigecycline in a rabbit model.Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK.The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery.Emerging 8-methoxyfluoroquinolone resistance among methicillin-susceptible Staphylococcus epidermidis isolates recovered from patients with endophthalmitis.Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis.Modeling intraocular bacterial infections.Gut microbiome-related metabolic changes in plasma of antibiotic-treated rats.In vitro moxifloxacin drug interaction with chemotherapeutics: implications for retinoblastoma management.The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.A super-infection in the cornea caused by Stemphylium, Acremonium, and α-Streptococcus.Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis.Comparison of aqueous humour concentration after single high dose versus multiple administration of topical moxifloxacin in rabbits.Severe bacterial endophthalmitis: towards improving clinical outcomesPharmacological treatment for infectious corneal ulcers.Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitisShort-term comparative study of the effects of preserved and unpreserved topical levofloxacin on the human ocular surface.In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States.The interaction of beta-lactoglobulin with ciprofloxacin and kanamycin; a spectroscopic and molecular modeling approach.
P2860
Q26752242-BF31B9FE-D2E5-49D0-9428-00A3B4F4A261Q26775838-078A3D8C-80E2-4177-A2F9-5B808CFB8923Q33706051-79CB2D6A-000A-489C-9E40-49ABDDE8CBD3Q33840867-3A6E4383-EEE9-4327-8B2E-A8FD99D6766AQ34769319-2105370C-65E8-4448-B3BD-A62BB42EF3DFQ35617621-CA43CA93-9A1D-4CA2-B581-EF95D8E501F1Q37125014-ABD0C11A-A84F-4906-9582-9CC857783F51Q37594797-011C3E7A-B49A-4E33-B376-976F2BB5A681Q38122147-C98920C5-75BB-4EC4-9666-E77CCE262EE9Q38827899-03B36958-D75F-4720-9BD9-E5F2F9254583Q38880638-876BBFD2-8557-4A6F-9E97-7BEE10AD93CFQ39071181-7D11D907-08D6-42C0-BAF3-5A55F8046204Q39747466-08B04FC1-26E5-4CD8-A761-34B8688A4B24Q40300591-2C2947D6-ABAF-4552-98E2-15D5442110B5Q41321186-C2D274EC-25ED-4606-9ACE-2598332A3DC5Q41647773-13C23BBD-BB22-4B8C-A57E-916BC72FC1D3Q41908007-EC1FE2C9-FB59-4C45-BD31-6F14F135CBEDQ42273313-A23EE0E0-45D0-407F-9E24-40C4C7A20244Q42729444-74417C12-9355-4B87-9E14-922FB8A2916AQ43021428-2A6A2016-0967-436C-AD04-B18560F17B18Q44755434-9DFEE93F-5736-4C6A-9357-2DA518863A16Q51549770-9887426A-EECB-4220-AA06-2F12E537A3CC
P2860
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review of third-and fourth-gen ...... in-vitro and in-vivo efficacy.
@en
Review of third-and fourth-gen ...... in-vitro and in-vivo efficacy.
@nl
type
label
Review of third-and fourth-gen ...... in-vitro and in-vivo efficacy.
@en
Review of third-and fourth-gen ...... in-vitro and in-vivo efficacy.
@nl
prefLabel
Review of third-and fourth-gen ...... in-vitro and in-vivo efficacy.
@en
Review of third-and fourth-gen ...... in-vitro and in-vivo efficacy.
@nl
P1433
P1476
Review of third-and fourth-gen ...... in-vitro and in-vivo efficacy.
@en
P2093
Stephen V Scoper
P2888
P304
P356
10.1007/S12325-008-0107-X
P407
P577
2008-10-01T00:00:00Z